The Latest

  • COUR Pharmaceuticals Announces Biotechnology Industry Veteran Robert F. Carey Joins Board of Directors as Lead Independent Director
  • Skip to primary navigation
  • Skip to main content
  • Skip to footer
COUR Pharmaceuticals Logo

COUR Pharmaceuticals

  • Our Company
    • Leadership
    • Advisors
    • Partners
    • Contact
  • Our Technology
    • Pipeline
    • Autoimmune Diseases
    • Allergies
    • Rare Diseases
    • Gene Therapy
  • Our Clinical Trials
  • Publications & Media
    • Press Releases
    • Publications
  • Careers

Partners

Takeda Logo

With COUR’s expertise in inflammatory diseases, Takeda is well positioned to further develop TAK-101 in pursuit of providing the first approved treatment option for patients with celiac disease, a multi-billion dollar market

Learn More About TAK-101
Ironwood Logo

COUR’s expertise in immune reprogramming coupled with Ironwood’s commercial strength and reach in GI position CNP-104 to be the first PBC product that treats the underlying drivers of disease instead of treating symptoms

Learn More About CNP-104

Please contact us if you have any business development inquires

Contact Us

Footer

COUR Pharmaceuticals Logo
  • Our Company
  • Our Technology
  • Our Partners
  • Press
  • Careers

©

2023

COUR Pharmaceuticals.
All Rights Reserved.

Privacy Policy • Terms of Use

Back to Top